Novo Nordisk A/S
Novo Nordisk A/S NOVC.DE Peers
See (NOVC.DE) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Pharmaceuticals Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| NOVC.DE | €91.40 | -1.98% | 406.7B | 22.91 | €3.99 | N/A |
| 4AB.DU | €164.80 | +0.24% | 291.1B | N/A | N/A | +3.21% |
| W8A.DE | €9.86 | -0.13% | 8.5B | -1.69 | -€5.84 | +5.79% |
| RDC.DE | €99.90 | -13.88% | 2B | -41.45 | -€2.41 | N/A |
| SAE.DE | €88.30 | N/A | 1.6B | -26.60 | -€3.32 | N/A |
| 2LYA.F | €2.03 | +1.25% | 163.9M | -40.50 | -€0.05 | N/A |
| NP5.DE | €7.93 | +0.76% | 158.3M | 9.33 | €0.85 | N/A |
| 5EA.DE | €19.20 | N/A | 0 | N/A | N/A | N/A |
Stock Comparison
NOVC.DE vs 4AB.DU Comparison
NOVC.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVC.DE stands at 406.7B. In comparison, 4AB.DU has a market cap of 291.1B. Regarding current trading prices, NOVC.DE is priced at €91.40, while 4AB.DU trades at €164.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVC.DE currently has a P/E ratio of 22.91, whereas 4AB.DU's P/E ratio is N/A. In terms of profitability, NOVC.DE's ROE is +0.86%, compared to 4AB.DU's ROE of +0.96%. Regarding short-term risk, NOVC.DE is more volatile compared to 4AB.DU. This indicates potentially higher risk in terms of short-term price fluctuations for NOVC.DE.